News articles about Corvus Pharmaceuticals (NASDAQ:CRVS) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.63241999152 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Corvus Pharmaceuticals (NASDAQ:CRVS) traded down $0.11 during trading on Friday, reaching $10.57. The company’s stock had a trading volume of 44,867 shares, compared to its average volume of 75,978. Corvus Pharmaceuticals has a 52-week low of $8.27 and a 52-week high of $22.14.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.19. sell-side analysts predict that Corvus Pharmaceuticals will post -2.82 earnings per share for the current year.
A number of brokerages have weighed in on CRVS. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Tuesday, November 7th. Credit Suisse Group upgraded Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 price target for the company in a report on Wednesday, August 23rd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Corvus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $20.25.
In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 10,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $10.79 per share, for a total transaction of $107,900.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 46.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Corvus Pharmaceuticals (CRVS) Receiving Somewhat Positive News Coverage, Analysis Shows” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://ledgergazette.com/2017/12/09/corvus-pharmaceuticals-crvs-receiving-somewhat-positive-news-coverage-analysis-shows.html.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.